GSK PLC GSK shares inched up 0.59% to £13.58 Tuesday, on what proved to be an all-around dismal trading session for the stock ...

The U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) on Tuesday sanctioned Mohammad Hamdan Daglo ...

Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

A live webcast of the presentation will be available on the investor section of the Anaptys website at A replay of the webcast will be available for at least 30 days following the event. About ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start" with more than 3,500 healthcare ...

The global pediatric vaccine market is set for unprecedented growth, with a valuation of US$ 54,130.1 million in 2023, ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.00.

(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration has granted a breakthrough therapy designation to its treatment for a form of bone cancer.